Determining context-specific economically feasible age ranges for female HPV catch-up vaccination in LMICs: a model-based health economic assessment

This model-based assessment of 132 low- and middle-income countries demonstrates that expanding female HPV catch-up vaccination up to age 30 is highly impactful and cost-effective for cervical cancer elimination, though its budgetary feasibility varies significantly and relies heavily on sustainable financing and Gavi support.

The Gist

Imagine the fight against cervical cancer as a massive, ongoing battle to stop a fire from spreading through a forest. For years, health organizations have focused on putting out the flames in the youngest saplings (girls aged 9–14) by giving them a protective shield (the HPV vaccine). This is the "routine" strategy, and it works well.

But here's the problem: many trees in the forest were planted before the fire-fighting plan started, or they missed the first round of protection. These are the young women and older girls who are now vulnerable. This study asks a crucial question: Should we go back and give the protective shield to these older trees, too?

The researchers, acting like expert forest planners, ran a massive simulation across 132 countries with lower incomes to see if it's worth the cost and effort to vaccinate women up to age 30.

Here is the breakdown of their findings, translated into everyday terms:

1. The "Firefighter" Analogy: Catch-Up Vaccination

Think of the HPV vaccine as a fire extinguisher.

• Routine Vaccination: This is handing out extinguishers to every 9-year-old girl. It stops new fires from starting.
• Catch-Up Vaccination: This is running back to the 15, 20, or even 29-year-olds who missed the first distribution to give them an extinguisher before the fire (cancer) can start.

The study found that if we do this "catch-up" for women up to age 30, we could prevent 9.2 million cases of cervical cancer over a lifetime. That's like saving the entire population of a large city from a devastating disease.

2. The "Wallet" Check: Is it Affordable?

The biggest worry for any country is: "Can we afford this?" The researchers looked at the price tag in two ways:

• The "Big Wallet" (Total Health Spending): They compared the cost of the vaccine campaign to the country's entire health budget. The result? It's surprisingly cheap. Even for the most ambitious plan (vaccinating up to age 30), it would only take up about 0.2% of a country's total health spending. It's like buying a cup of coffee for a family of millions.
• The "Piggy Bank" (Immunization Budget): This is the specific money set aside for vaccines. Here, the cost is higher, ranging from tiny fractions to over 200% of the budget in some places. This means some countries would need extra help to pay for it.

The Good News: About 70% of the cost is just buying the vaccine itself. If countries get help from global donors (like Gavi), the price tag drops by nearly 70%. It's like getting a massive discount coupon that makes the "catch-up" plan much easier to afford.

3. The "Value for Money" Test

The researchers asked: "Is this a good deal?"
They looked at six different countries representing different parts of the world. In almost every case, the answer was a resounding YES.

• The "Cost-Saving" Scenario: In some places (like Eswatini), treating cervical cancer is incredibly expensive because patients have to travel to private hospitals in other countries. In these cases, giving the vaccine actually saves money in the long run. It's cheaper to buy the vaccine than to pay for the surgery and treatment later.
• The "Worth It" Scenario: In other places, the vaccine isn't free, but it's so effective at stopping cancer that it's still considered a "best buy." It's like buying a high-quality roof for your house; it costs money upfront, but it saves you from paying thousands in flood damage later.

4. The "Diminishing Returns" Reality

The study also looked at how effective the vaccine is as women get older.

• Younger Women (10–15): The vaccine is like a brand-new, super-strong shield. It works perfectly because they likely haven't been exposed to the virus yet.
• Older Women (25–30): The shield is still very useful, but slightly less "perfect" because some women may have already been exposed to the virus. However, it's still strong enough to stop the virus from causing cancer.
• The Sweet Spot: The study suggests that going up to age 30 is the "sweet spot." Going beyond that adds very little benefit because the virus has likely already done its damage, but stopping at 30 captures the vast majority of the remaining risk.

5. The Bottom Line

The researchers conclude that while the primary focus should always be on vaccinating young girls (9–14), ignoring the older girls and young women is a missed opportunity.

Think of it this way: If you are trying to stop a leak in a boat, you patch the big hole first (the young girls). But if you leave the smaller holes (the older women) open, the boat will still sink eventually. Patching those holes is affordable, it saves lives, and in many cases, it saves money.

The Takeaway for Policymakers:
Don't just vaccinate the little ones and stop. If you have the budget (or can get help from international donors), expand the net to catch women up to age 30. It's a smart investment that will pay off by preventing millions of cancers and saving countless lives.

Technical Summary

1. Problem Statement

Despite global efforts to eliminate cervical cancer, approximately one-third of women worldwide live in countries without HPV vaccination programs, and coverage remains suboptimal even where introduced. Current strategies in Low- and Middle-Income Countries (LMICs) primarily target girls aged 9–14 years. While "catch-up" vaccination (vaccinating older cohorts who missed routine immunization) is known to reduce HPV incidence, there is a lack of evidence regarding:

• The economically feasible upper age limits for catch-up vaccination across diverse LMIC contexts.
• The budget impact of extending these programs beyond age 14 or 18.
• The cost-effectiveness of single-dose catch-up strategies for women up to age 30, particularly given resource constraints and varying sexual behavior patterns.

2. Methodology

The study utilized a comprehensive modeling approach based on the IARC/WHO METHIS platform, integrating two validated models:

• RHEA (HPV Transmission Model): Simulates the transmission of 13 high-risk HPV types through sexual contact, parameterized by age, sex, and sexual activity levels.
• ATLAS (Cervical Cancer Progression Model): Estimates reductions in cervical cancer cases and deaths based on RHEA outputs and regional HPV type-specific attributable fractions.

Study Design & Data:

• Scope: 132 LMICs were analyzed. Countries were grouped into sexual behavior clusters derived from Demographic and Health Surveys (DHS) to account for epidemiological heterogeneity.
• Intervention: A one-time, single-dose catch-up vaccination campaign in 2026 for females aged 10–30 years, added to routine vaccination for 9-year-olds.
• Comparators: Routine vaccination of 9-year-olds only (no catch-up).
• Vaccine Assumptions: Single-dose schedule with 95% efficacy against HPV 16/18 and 9% cross-protection against types 31, 33, and 45. Lifelong protection was assumed.
• Costing:
  • Budget Impact: Calculated for all 132 countries using vaccine procurement prices (MI4A database) and delivery costs (school-based for 9–14, mixed for 15–18, community outreach for ≥19). Results were expressed as a percentage of 5-year immunization budgets and Current Health Expenditure (CHE).
  • Cost-Effectiveness: Conducted on a subset of 6 representative countries (Colombia, Eswatini, India, Indonesia, Kenya, Nigeria) selected for high-quality cervical cancer treatment cost data.
  • Metrics: Incremental Cost-Effectiveness Ratio (ICER) per Disability-Adjusted Life Year (DALY) averted. Thresholds used were 30% and 100% of GDP per capita. Costs were discounted at 3%; DALYs at 0%.

3. Key Contributions

• First Multi-Country Budget Impact Analysis: This is the first study to estimate the budget impact of HPV catch-up vaccination across 132 LMICs, providing a granular view of affordability relative to national health budgets.
• Context-Specific Age Limits: Instead of a universal age cutoff, the study provides evidence for context-specific maximum age ranges based on local economic conditions and sexual behavior clusters.
• Single-Dose Evaluation: The analysis specifically evaluates the feasibility of catch-up under the WHO-endorsed single-dose schedule, which is critical for LMICs with limited resources.
• Gavi Impact Quantification: The study quantifies the potential budget relief provided by Gavi support, showing a nearly 70% reduction in costs for eligible countries.

4. Key Results

Health Impact:

• Catch-up vaccination up to age 30 across 132 LMICs could prevent 9.2 million cervical cancer cases over the lifetime of females aged 9–30.
• This is a significant increase compared to routine vaccination alone (which would prevent 1.6 million cases).
• The highest burden averted is in the WHO South-East Asia Region (3.4 million cases) and African Region (3.1 million cases).

Budget Impact:

• Relative to CHE: The median budget impact is 0.09% of 5-year CHE for catch-up to age 18, rising to 0.20% for catch-up to age 30.
• Relative to Immunization Budgets: The impact is more substantial here, ranging from a median of 9.44% (up to age 18) to 21.68% (up to age 30).
• Cost Drivers: Vaccine procurement accounts for approximately 70% of total program costs.
• Gavi Support: For Gavi-eligible countries, support could reduce the national budget requirement by ~69.5% for catch-up up to age 18.

Cost-Effectiveness (Selected Countries):

• Catch-up vaccination up to age 30 was cost-effective in almost all evaluated countries.
• Eswatini: The program was cost-saving (less costly and more effective) across all age ranges up to 30 due to high treatment costs (often requiring cross-border care).
• Kenya & India: Cost-saving up to ages 19 and 20, respectively; remained cost-effective up to age 30.
• Nigeria: Cost-effective up to age 21 (the lowest GDP per capita among the analyzed group).
• Colombia & Indonesia: Cost-effective up to age 30.
• Diminishing Returns: ICERs increased with each additional year of age, indicating diminishing marginal returns, but the intervention remained below the cost-effectiveness thresholds.

5. Significance and Implications

• Policy Guidance: The study provides robust evidence that expanding HPV catch-up vaccination beyond the primary target (9–14 years) is a "best buy" intervention for LMICs. It supports the WHO's goal of cervical cancer elimination by accelerating incidence reduction.
• Strategic Planning: Policymakers are advised to prioritize high coverage in the 9–14 age group first, then expand catch-up limits based on fiscal space and delivery capacity.
• Financing: The findings highlight the critical need for sustainable financing mechanisms, including Gavi support and technology transfer for local manufacturing, to manage the procurement costs which dominate the budget.
• Integration: Integrating catch-up vaccination into existing platforms (e.g., reproductive health clinics) is recommended to improve operational efficiency and reach out-of-school girls.
• Economic Argument: The study reframes vaccination as an investment rather than an expense, noting that the cost of inaction (preventable deaths, treatment costs, and loss of productivity) far exceeds the cost of the vaccine program.

Limitations: The study did not model past vaccination coverage (estimates represent maximum potential impact), excluded low-income countries from cost-effectiveness analysis due to data scarcity, and did not account for HIV status (though sensitivity analysis suggested this would not alter the main conclusions).